Segment Disclosures and Concentrations of Risk - Schedule of Reported Segment Revenues and Profit or Loss, Net of Intersegment Eliminations, and Reconciliation (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
		Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Revenue	[1]	$ 254,909		$ 303,897	$ 855,162	$ 858,369
Income (loss) before income taxes		(40,174)		18,593	(218,808)	54,428
Acquisition, integration and project costs		2,485		5,259	7,331	31,306
Transaction-related costs		2,755			2,755
Impairment loss		66,198	$ 199,500		265,698
COVID-19 costs		591			1,851
Restructuring and related charges		1,136		281	2,888	4,225
Interest expense		20,395		23,006	63,294	54,334
Depreciation and amortization		13,315		9,700	40,997	22,366
Adjusted EBITDA		68,692		56,839	172,329	166,659
CEO
Segment Reporting Information [Line Items]
CEO transition costs		1,991			6,323
Healthcare
Segment Reporting Information [Line Items]
Revenue		95,481		159,979	337,096	473,987
Adjusted EBITDA		40,965		39,177	112,686	100,986
Nutrition
Segment Reporting Information [Line Items]
Revenue		159,428		143,918	518,066	384,382
Adjusted EBITDA		$ 27,727		$ 17,662	$ 59,643	$ 65,673

[1] The figure for total segments equals the consolidated figure for such item.